Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

A. The Assessment Report for this appraisal was prepared by The School of Health and Related Research (ScHARR):

Hind D, Ward S, De Nigris E, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation, January 2006.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination.

I) Manufacturers/sponsors:

  • Astra Zeneca

  • Novartis Pharma

  • Pfizer

II) Professional/specialist and patient/carer groups:

  • Breakthrough Breast Cancer

  • Breast Cancer Care

  • Breast Cancer Campaign

  • Cancerbackup

  • Association of Surgeons of Great Britain and Ireland

  • British Association of Surgical Oncology

  • British Oncology Pharmacy Association (BOPA)

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal Pharmaceutical Society

  • Society of Endocrinology

  • Department of Health

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • British National Formulary

  • Medicines and Healthcare Products Regulatory Agency (MHRA)

  • NHS Quality Improvement Scotland

  • AstraZeneca

  • Institute of Cancer Research

  • National Cancer Research Institute

  • National Coordinating Centre for Health Technology Assessment

  • School of Health and Related Research, Sheffield

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on hormonal therapies for the adjuvant treatment of breast cancer by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Mr Derek Crawford, Consultant Surgeon, Llandudno General Hospital – clinical expert nominated by British Association of Surgical Oncology

  • Professor Ian Smith, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust – clinical expert nominated by the Institute of Cancer Research

  • Mrs Stephanie Jacobs, Chair, Breast Cancer Care – patient expert nominated by Breast Cancer Care

  • Mrs Carolyn Morris – patient expert nominated by Cancer Voices

D. The following individual(s) representing the National Collaborating Centre responsible for developing the Institute's clinical guideline on early breast cancer guidelines were invited to attend the ACD meeting as observers and to contribute as advisors to the Committee.

  • Dr Adrian Harnett, Consultant in Clinical Oncology, Norfolk and Norwich University Hospital NHS Trust